ArticleJournal of clinical laboratory analysis2026
Synthesis, Antitumor Activity Evaluation and Mechanistic Study of Novel Bis-Heterocyclic Chalcones Against Liver Cancer.
Article in Journal of clinical laboratory analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChalcones and heterocyclic compounds exhibit remarkably high activity in medicinal chemistry. In recent years, bis-chalcones have been reported to possess excellent anticancer activity. We synthesized a series of bis-heterocyclic chalcones via asymmetric chain synthesis, with the aim of making new discoveries in anticancer activity.
methodsBis-heterocyclic chalcones were synthesized via Claisen-Schmidt condensation and alkylation reactions. The inhibitory activities of the synthesized compounds against Huh-1, Huh-7, and HepG2 cell lines were evaluated using the CCK-8 assay. Furthermore, the mechanism of action of these compounds was explored through live/dead cell staining, flow cytometric analysis, and Western blotting experiments.
resultsTwelve bis-heterocyclic chalcone compounds were synthesized. All synthesized compounds were fully characterized by spectroscopic methods and evaluated for their cytotoxic activities against Huh-1, Huh-7, and HepG2 cell lines using the CCK-8 assay at concentrations ranging from 0 to 100 μM. Among them, derivative 3f exhibited the most potent cytotoxicity against Huh-7 (IC
conclusionsBis-heterocyclic chalcone compounds exhibit favorable inhibitory activity against hepatocellular carcinoma cells by inducing cell apoptosis, and thus can serve as a class of pharmaceutically active structural units for further in-depth research and screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.